Results 51 to 60 of about 8,387 (169)

Lipid Storage Myopathy in Behçet's Disease: A Rare Cause of Elevated Serum Creatine Kinases Levels

Case Reports in Rheumatology, 2012
Muscular involvement in Behçet’s disease is rare and there are only a few case reports in the literature. The causes of elevated muscle enzymes in a patient with Behcet’s disease are many, including myositis, drug-induced myopathy, metabolic myopathy ...
Sedat Yilmaz, Muhammet Cinar, Yıldırım Karslioglu, Ismail Simsek, Hakan Erdem, Salih Pay, Ayhan Dinc   +6 more
doaj   +1 more source

When to consider an inborn error of immunity: clues for physicians

Internal Medicine Journal, EarlyView.
Abstract The term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described.
Meera Thangarajah, Lucinda J. Berglund
wiley   +1 more source

Malignant lymphoma associated with Behçet’s disease: A report of 2 cases

Turkish Journal of Hematology, 2011
Herein we report 2 cases of malignant lymphoma associated with Behçet’s disease. Case 1, a 53-year-old man, was diagnosed as Behçet’s disease at the age of 26 years, and was treated with cyclophosphamide and prednisolone.
Ahmet Deniz Meydan, Bilge Gürsel, Nilgün Özbek, Bilge Can, Bilge Can   +4 more
doaj   +3 more sources

A rare involvement in Behcet's Disease: Carotid artery aneurysm

İstanbul Kuzey Klinikleri, 2017
Behçet's disease is an inflammatory disease characterized by recurrent oral aphthous ulcers and various accompanying systemic pathologies. These additional pathologies include ocular and neurologic disease, genital ulcers, skin lesions, arthritis and ...
Hamit Serdar Başbuğ, Yalçın Günerhan, Hakan Göçer, Kanat Özışık   +3 more
doaj   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

T LYMPHOCYTE SUBGROUPS IN THE PATIENTS WITH ACTIVE AND INACTIVE BEHÇET’S DISEASE

Eurasian Journal of Medicine, 2019
Immunological changes have an important role in the etiopathogenesis of Behçet's disease. Inflammation derived by immunological mechanisms is responsible from the signs and findings of disease.
Refik Ali Sarı, Mehmet Şahin, Necmettin Akdeniz, İlhami Kiki   +3 more
doaj  

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Correlation of Otorhinolaryngologic Symptoms with Physical Findings in Behçet’s Disease

B-ENT, 2015
Correlation of Otorhinolaryngologic Symptoms with Physical Findings in Behçet’s Disease. Objective: Behçet’s disease is a chronic systemic inflammatory disease of unknown etiology.
A. Meric, R. Dogan, O. Su, S. B. Eren, S. Tugrul, O. Ozturan   +5 more
doaj   +2 more sources

Brain biopsy to aid diagnosis of neuro-Behçet's disease: Case report and literature review

eNeurologicalSci, 2017
Central nervous system involvement in Behçet's disease (Neuro-Behçet's disease: NBD) has been reported to present diverse clinical and pathological manifestations.
Hiroki Yamada, Kazuyuki Saito, Mitsuhiko Hokari, Shuta Toru   +3 more
doaj   +1 more source

Measuring success in HS treatment from the physician's and the patient's perspective

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Integrated clinician (HiSCR, IHS4, IHS4‐55, HS‐IGA) and patient (HiSQOL, DLQI) scores, combined with imaging‐based fibrosis and inflammation assessment, redefine treatment success in hidradenitis suppurativa by aligning treat‐to‐target strategies with both inflammatory control and irreversible structural damage.
Georgios Nikolakis, Monika Arenbergerova, Zeljko Mijuskovic, Baoxi Wang, Christos C. Zouboulis   +4 more
wiley   +1 more source